CFO
RLAY icon

Callan Family Office’s Relay Therapeutics RLAY Stock Holding History

Callan Family Office’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$335K Buy
17,916
+26
+0.1% +$377 0.01% 957
2026
Q1 		$178K Sell
17,890
-2,641
-13% -$23.6K ﹤0.01% 1071
2025
Q4 		$174K Buy
+20,531
New +$147K ﹤0.01% 1063

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Callan Family Office's RLAY Position: Q2 2026 in Review

Callan Family Office increased its Relay Therapeutics (RLAY) stake by 0.15% in Q2 2026, buying an estimated $377 and bringing the position to 17,916 shares worth $335K. The position accounts for 0.01% of the portfolio, ranked #957.

Callan Family Office first reported a position in RLAY in Q4 2025 and has held it in 3 quarters since. 258 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • Callan Family Office held 17,916 shares of Relay Therapeutics worth $335K as of Q2 2026.
  • Callan Family Office bought 26 Relay Therapeutics shares in Q2 2026, an estimated $377.
  • Relay Therapeutics made up 0.01% of Callan Family Office's portfolio in Q2 2026, its #957 holding.
  • Callan Family Office first reported a position in Relay Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 258 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on Callan Family Office's 13F filing for Q2 2026, filed 11 Aug 2026.